AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28102 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard neuroleptics
Number of subjects: 181
Study 28102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipotiazine palmitate
Number of subjects: 181
Study 28102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 181
Study 30581069 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX (D1 bolus removed)
Number of subjects: 188
Study 30581069 — intervention group
Group type: COMPARATOR
Intervention: CisGem (Cisplatin and Gemcitabine)
Number of subjects: 188
Study 30581069 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFIRINOX
Number of subjects: 188
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast feeding
Number of subjects: 10
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow feeding
Number of subjects: 10
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative state
Number of subjects: 10
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative state
Number of subjects: 10
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake
Number of subjects: 10
Study 27022941 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 10
Study 26189253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiotherapy (IMRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Number of subjects: 72
Study 26189253 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D CRT) with concurrent chemotherapy (nedaplatin 30 mg/m2 weekly for six cycles)
Number of subjects: 72
Study 26189253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D CRT groups
Number of subjects: 72
Study 23656836 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive strategy promoting adherence to laboratory confirmation of malaria before treatment at facility-level
Number of subjects: 18
Study 21451017 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI) measurements
Number of subjects: 0
Study 21451017 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate pattern analysis methods
Number of subjects: 0
Study 21451017 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoding stimulus attributes and cognitive states from fMRI measurements
Number of subjects: 0
Study 19089321 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine/Montelukast (L/M) 10 mg/10 mg
Number of subjects: 23
Study 19089321 — intervention group
Group type: COMPARATOR
Intervention: Diphenhydramine 50 mg
Number of subjects: 23
Study 19089321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 16772315 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced mandibular advancement device (MAD)
Number of subjects: 23
Study 16772315 — intervention group
Group type: COMPARATOR
Intervention: Non-advanced mandibular advancement device (MAD)
Number of subjects: 23
Study 15557944 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent with windsock-type antireflux valve (FerX-Ella) (n = 15)
Number of subjects: 30
Study 15557944 — intervention group
Group type: COMPARATOR
Intervention: Standard open stent (n = 15)
Number of subjects: 30
Study 11535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diltiazem (60 mg, twice daily for up to eight weeks)
Number of subjects: 50
Study 11535842 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem (2 percent gel, twice daily for up to eight weeks)
Number of subjects: 50
Study 9024445 — intervention group
Group type: EXPERIMENTAL
Intervention: HAB (Histoacryl Blue)
Number of subjects: 61
Study 9024445 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 61
Study 8394651 — intervention group
Group type: COMPARATOR
Intervention: MCPP (0.35 mg/kg p.o.)
Number of subjects: 19
Study 8394651 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (up to 600 mg/day for 5 weeks)
Number of subjects: 19
Study 8394651 — intervention group
Group type: COMPARATOR
Intervention: MCPP
Number of subjects: 19
Study 3314538 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT
Number of subjects: 52
Study 3314538 — intervention group
Group type: COMPARATOR
Intervention: Unilateral right ECT
Number of subjects: 52
Study 29903845 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline adiponectin
Number of subjects: 6998
Study 29903845 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in adiponectin from baseline to month 3
Number of subjects: 6998
Study 29903845 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FFAs
Number of subjects: 6998
Study 29903845 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FFAs from baseline
Number of subjects: 6998
Study 27044585 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT and nutrition advice
Number of subjects: 100
Study 27044585 — intervention group
Group type: EXPERIMENTAL
Intervention: MICT and nutrition advice
Number of subjects: 100
Study 27044585 — intervention group
Group type: COMPARATOR
Intervention: Nutrition advice
Number of subjects: 100
Study 23363371 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii Fit intervention (10 min thrice weekly for 1 month)
Number of subjects: 18
Study 23363371 — intervention group
Group type: COMPARATOR
Intervention: Regular Jump Ahead programme (comparison group)
Number of subjects: 18
Study 22926339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution microendoscope (HRME) imaging system
Number of subjects: 174
Study 22926339 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection with acetic acid (VIA) and colposcopic examination
Number of subjects: 174
Study 22926339 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk human papilloma virus (HPV) DNA testing
Number of subjects: 174
Study 20438354 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus
Number of subjects: 128
Study 20438354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany (hand mixed)
Number of subjects: 128
Study 20438354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany (automix syringe)
Number of subjects: 128
Study 20438354 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit Plus
Number of subjects: 128
Study 20438354 — intervention group
Group type: COMPARATOR
Intervention: 17% EDTAC
Number of subjects: 128
Study 20438354 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 128
Study 20438354 — intervention group
Group type: COMPARATOR
Intervention: 1% NaOCl
Number of subjects: 128
Study 20438354 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 128
Study 18656328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of enalapril plus 0.4 mg of folic acid (low‐FA group)
Number of subjects: 480
Study 18656328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of enalapril plus 0.8 mg of folic acid (high‐FA group)
Number of subjects: 480
Study 18656328 — intervention group
Group type: COMPARATOR
Intervention: 10 mg of enalapril (control group)
Number of subjects: 480
Study 16301338 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlessness (acute 20‐s periods in parabolic airplane flights)
Number of subjects: 12
Study 16301338 — intervention group
Group type: EXPERIMENTAL
Intervention: Weightlessness (after a week in space)
Number of subjects: 12
Study 16301338 — intervention group
Group type: COMPARATOR
Intervention: Seated 1‐G position (reference)
Number of subjects: 12
Study 12665407 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable-frequency train (VFT) stimulation
Number of subjects: 10
Study 12665407 — intervention group
Group type: COMPARATOR
Intervention: Constant-frequency train (CFT) stimulation
Number of subjects: 10
Study 10811043 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 133
Study 10811043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 8711491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) with low-dose recombinant tissue-type plasminogen activator (rt-PA) (0.02 to 0.05 mg/h)
Number of subjects: 0
Study 8711491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT)
Number of subjects: 0
Study 8711491 — intervention group
Group type: COMPARATOR
Intervention: Surgical revascularization
Number of subjects: 0
Study 1509913 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hormonal blockade (orchiectomy + flutamide)
Number of subjects: 70
Study 1509913 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (orchiectomy only)
Number of subjects: 70
Study 1509913 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (part of complete blockade)
Number of subjects: 70
Study 1509913 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete hormonal blockade
Number of subjects: 70
Study 1509913 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 70
Study 6871626 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol and a balanced electrolyte solution (PEG + E)
Number of subjects: 77
Study 31659967 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom model (Group B)
Number of subjects: 40
Study 31659967 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic lecture (Group A)
Number of subjects: 40
Study 30278479 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary drainage (interventional therapy)
Number of subjects: 90
Study 30278479 — intervention group
Group type: COMPARATOR
Intervention: Radical/palliative surgery (conventional group)
Number of subjects: 90
Study 25847473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) ingestion for 3 weeks before and after vaccination
Number of subjects: 0
Study 25847473 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cocoa ingestion)
Number of subjects: 0
Study 25847473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract (CE) ingestion
Number of subjects: 0
Study 24332423 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-Eluting Stents (EES)
Number of subjects: 1498
Study 24332423 — intervention group
Group type: COMPARATOR
Intervention: Bare-Metal Stents (BMS)
Number of subjects: 1498
Study 22004457 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg tid
Number of subjects: 618
Study 22004457 — intervention group
Group type: COMPARATOR
Intervention: Teprenone 50 mg tid
Number of subjects: 618
Study 18704618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive Bupivacaine (PBU) - 10 ml 0.5% Bupivacaine to port sites before skin incision and another 10 ml to the preperitoneal space immediately after the creation of a first working port.
Number of subjects: 90
Study 18704618 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Bupivacaine (SBU) - Infiltration of Bupivacaine after mesh placement.
Number of subjects: 90
Study 18704618 — intervention group
Group type: COMPARATOR
Intervention: Control (CO) - Saline injection instead of Bupivacaine.
Number of subjects: 90
Study 17450086 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 24
Study 17450086 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 24
Study 15367189 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% CHX spray (test group)
Number of subjects: 20
Study 15367189 — intervention group
Group type: COMPARATOR
Intervention: 0.12% CHX mouthrinse (control group)
Number of subjects: 20
Study 11592918 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant P64k (20 or 50 microg)
Number of subjects: 18
Study 11592918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9555822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% tretinoin gel containing polyolprepolymer‐2
Number of subjects: 215
Study 9555822 — intervention group
Group type: COMPARATOR
Intervention: 0.025% commercially‐available tretinoin gel
Number of subjects: 215
Study 9555822 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 215
Study 9555822 — intervention group
Group type: EXPERIMENTAL
Intervention: Both active medications
Number of subjects: 215
Study 8275406 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT vaccine (group A, 99 children)
Number of subjects: 200
Study 8275406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pertussis vaccine (group A, 99 children)
Number of subjects: 200
Study 8275406 — intervention group
Group type: EXPERIMENTAL
Intervention: DT vaccine (group B, 101 children)
Number of subjects: 200
Study 8275406 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pertussis vaccine
Number of subjects: 200
Study 2542197 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone (RT) (50 Gy large field and 10 Gy boost)
Number of subjects: 268
Study 2542197 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy combined with misonidazole (400 mg/m2 2‐4 hr prior to RT daily for 5‐6 weeks)
Number of subjects: 268
Study 29733400 — intervention group
Group type: EXPERIMENTAL
Intervention: ILO once monthly (group B)
Number of subjects: 96
Study 29733400 — intervention group
Group type: EXPERIMENTAL
Intervention: ILO for five consecutive days (group C)
Number of subjects: 96
Study 29733400 — intervention group
Group type: COMPARATOR
Intervention: No ILO (group A)
Number of subjects: 96
Study 28025364 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Blind Placebo Lead-in (SBPLI)
Number of subjects: 0
Study 25638597 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day whey protein-supplemented beverage
Number of subjects: 219
Study 25638597 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched low-protein high-carbohydrate beverage (control)
Number of subjects: 219
Study 22818976 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis (DO) of the mandibular anterior alveolar process
Number of subjects: 19
Study 22818976 — intervention group
Group type: COMPARATOR
Intervention: Control group (orthodontically treated patients)
Number of subjects: 19
Study 21040143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (Gamunex)
Number of subjects: 117
Study 21040143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 21040143 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamunex
Number of subjects: 117
Study 17368909 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rotation
Number of subjects: 61
Study 17368909 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group I)
Number of subjects: 61
Study 16550750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (La)
Number of subjects: 1359
Study 16550750 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (any approved phosphate binder)
Number of subjects: 1359
Study 14972204 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient feedback (SP)
Number of subjects: 8
Study 14972204 — intervention group
Group type: COMPARATOR
Intervention: No standardized patient feedback (Control)
Number of subjects: 8
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed HQL questionnaire
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview HQL questionnaire
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed PDQ-39 Social Support subscale
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview PDQ-39 Social Support subscale
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview PDQ-39 Cognitions subscale
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed SF-36 General Health subscale
Number of subjects: 150
Study 10981209 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-completed SF-36 Social Function subscale
Number of subjects: 150
Study 10981209 — intervention group
Group type: COMPARATOR
Intervention: Patients at later clinical stages
Number of subjects: 150
Study 10981209 — intervention group
Group type: COMPARATOR
Intervention: Patients with dyskinesias
Number of subjects: 150
Study 10981209 — intervention group
Group type: COMPARATOR
Intervention: Patients with self-reported comorbidities
Number of subjects: 150
Study 8783327 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac plexus block (CPB)
Number of subjects: 21
Study 8783327 — intervention group
Group type: COMPARATOR
Intervention: NSAID‐morphine treatment
Number of subjects: 21
Study 1479003 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Number of subjects: 20
Study 1479003 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.87 mg D‐Trp‐6‐luteinizing hormone-releasing hormone (LHRH)
Number of subjects: 20
Study 2410686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 2410686 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 0
Study 2410686 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimazosin
Number of subjects: 0
Study 2410686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin and Doxazosin
Number of subjects: 0
Study 30832454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 43
Study 30832454 — intervention group
Group type: EXPERIMENTAL
Intervention: Core Stability Training (CST)
Number of subjects: 43
Study 29671368 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin E
Number of subjects: 0
Study 29671368 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) + vitamin C
Number of subjects: 0
Study 29671368 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical human amniotic membrane-mesenchymal stem cell-conditioned medium (hAMMSC-CM) alone
Number of subjects: 0
Study 29671368 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 26359346 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent physical activity intervention
Number of subjects: 1150
Study 24521245 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide (LIXI) 20 µg
Number of subjects: 2
Study 24521245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 22468806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 1,800 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 103
Study 22468806 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed 600 mg/m2 plus cyclophosphamide 600 mg/m2
Number of subjects: 103
Study 20230403 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 73
Study 18339046 — intervention group
Group type: EXPERIMENTAL
Intervention: Amber tinted contact lens
Number of subjects: 13
Study 18339046 — intervention group
Group type: EXPERIMENTAL
Intervention: Grey-green tinted contact lens
Number of subjects: 13
Study 18339046 — intervention group
Group type: COMPARATOR
Intervention: Clear contact lens (Optima 38)
Number of subjects: 13
Study 15655124 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril with or without hydrochlorothiazide, or nifedipine or an angiotensin receptor blocker for uncontrolled hypertensive subjects
Number of subjects: 51
Study 15655124 — intervention group
Group type: COMPARATOR
Intervention: Observation (no treatment) for normotensive and treated hypertensive subjects
Number of subjects: 51
Study 12011292 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta1a
Number of subjects: 0
Study 9861443 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenselect (free form of catechins)
Number of subjects: 0
Study 9861443 — intervention group
Group type: EXPERIMENTAL
Intervention: Greenselect Phytosome (phospholipid complex form)
Number of subjects: 0
Study 7796586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral monophasic contraceptive (ethinylestradiol 20 micrograms + desogestrel 0.150 mg)
Number of subjects: 200
Study 7796586 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 200
Study 7796586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 200
Study 2356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic diflunisal (two tablets immediately at the conclusion of the visit, then four tablets to be taken in the schedule of one every 8 to 12 hours for pain if needed)
Number of subjects: 100
Study 2356085 — intervention group
Group type: COMPARATOR
Intervention: On-demand diflunisal (same dosage schedule; pills to be taken only if needed)
Number of subjects: 100
Study 517519 — intervention group
Group type: EXPERIMENTAL
Intervention: 47,XXY men
Number of subjects: 78
Study 517519 — intervention group
Group type: COMPARATOR
Intervention: Matched controls with 46,XY
Number of subjects: 78
Study 517519 — intervention group
Group type: EXPERIMENTAL
Intervention: 47,XYY men
Number of subjects: 78
Study 31334393 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-stroke back massage (n=30)
Number of subjects: 60
Study 31334393 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 60
Study 28916142 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 50
Study 28916142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 26689281 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-quit nicotine patch treatment (two weeks of patch treatment prior to a quit day, followed by 10 weeks post-quit treatment)
Number of subjects: 216
Study 26689281 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (starting two weeks prior to quit day followed by 10 weeks post-quit)
Number of subjects: 216
Study 26689281 — intervention group
Group type: COMPARATOR
Intervention: Standard patch treatment (10 weeks of patch starting from a designated quit day)
Number of subjects: 216
Study 24170536 — intervention group
Group type: EXPERIMENTAL
Intervention: Rad technique
Number of subjects: 62
Study 24170536 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 62
Study 21380937 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (4.5 mg daily)
Number of subjects: 40
Study 21380937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40